Erratum: Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 6. Youth, women, and the elderly (Canadian Journal of Psychiatry (2016) 61:9 (588-603) DOI: 10.1177/0706743716659276);Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 6. Special populations: Youth, women, and the elderly

Canadian Journal of Psychiatry

Volumn 61, Issue 9, 2016, Pages 588-603

  MacQueen, Glenda M ^a   Frey, Benicio N ^b   Ismail, Zahinoor ^a   Jaworska, Natalia ^c   Steiner, Meir ^b   Lieshout, Ryan J Van ^b   Kennedy, Sidney H ^d   Lam, Raymond W ^e   Milev, Roumen V ^f   Parikh, Sagar V ^d,g   Ravindran, Arun V ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f QUEEN S UNIVERSITY   (Canada)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Child and adolescent psychiatry; Clinical practice guidelines; Evidence based medicine; Geriatric psychiatry; Major depressive disorder; Maternal health; Meta analysis; Perinatal; Postpartum; Systematic reviews

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOMIPRAMINE; DESVENLAFAXINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; ESTRADIOL; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; NORTRIPTYLINE; OMEGA 3 FATTY ACID; PAROXETINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADOLESCENT; ADULT; AGED; AUTISM; BEHAVIOR DISORDER; BREAST FEEDING; CANADA; CARDIOVASCULAR MALFORMATION; CLIMACTERIUM; COGNITIVE BEHAVIORAL THERAPY; COGNITIVE DEFECT; COMORBIDITY; CONGENITAL MALFORMATION; CONSENSUS; COUPLE THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; EMOTIONAL DISORDER; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPONATREMIA; JUVENILE; LANGUAGE DISABILITY; LATE LIFE DEPRESSION; MAJOR DEPRESSION; META ANALYSIS (TOPIC); MINDFULNESS; NEUROLEPTIC MALIGNANT SYNDROME; PERIMENOPAUSAL DEPRESSION; PERINATAL DEPRESSION; PERSISTENT PULMONARY HYPERTENSION; PRACTICE GUIDELINE; PREGNANT WOMAN; PSYCHODYNAMIC PSYCHOTHERAPY; PSYCHOTHERAPY; PUERPERAL DEPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS; REVIEW; SEROTONIN SYNDROME; SIDE EFFECT; SPONTANEOUS ABORTION; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; SYSTEMATIC REVIEW (TOPIC); TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESISTANT DEPRESSION; TREMOR; UNSPECIFIED SIDE EFFECT; CHILD; CHILD PSYCHIATRY; FEMALE; GERONTOPSYCHIATRY; META ANALYSIS; PREGNANCY; PREGNANCY COMPLICATION; PROCEDURES; STANDARDS;

ADOLESCENT PSYCHIATRY; ADULT; AGED; CANADA; CHILD; CHILD PSYCHIATRY; DEPRESSIVE DISORDER, MAJOR; EVIDENCE-BASED MEDICINE; FEMALE; GERIATRIC PSYCHIATRY; HUMANS; PERIMENOPAUSE; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84986919208     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/0706743717708346     Document Type: Erratum

References (145)

1. Kennedy SH, Lam RW, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. Introduction. J Affect Disord. 2009;117(Suppl 1):S1-S2.
2. Lam RW, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: introduction and methods. Can J Psychiatry. 2016;61(9):506-509.
3. Santaguida PL, MacQueen G, Kashavarz H, et al. Treatment for depression after unsatisfactory response to SSRIs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012. Report No.: 12-EHC050-EF. AHRQ Comparative Effectiveness Reviews.
4. Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2015. HHS Publication No. SMA 15-4927, NSDUH Series H-50.
5. Pearson C, Janz T, Ali J. Mental and substance use disorders in Canada [Internet]. Ottawa (ON): Statistics Canada; 2013 [cited 2016 June 10]. Catalogue no. 82-624-X. Available from: http://www.statcan. gc.ca/pub/82-624-x/2013001/article/11855-eng.pdf
6. Casey BJ, Jones RM, Hare TA. The adolescent brain. Ann N Y Acad Sci. 2008;1124:111-126.
7. Stockings E, Degenhardt L, Lee YY, et al. Symptom screening scales for detecting major depressive disorder in children and adolescents: a systematic review and meta-analysis of reliability, validity and diagnostic utility. J Affect Disord. 2015;174:447-463.
8. Lewandowski RE, Acri MC, Hoagwood KE, et al. Evidence for the management of adolescent depression. Pediatrics. 2013;132:e996-e1009.
9. Choe CJ, Emslie GJ, Mayes TL. Depression. Child Adolesc Psychiatr Clin North Am. 2012;21:807-829.
10. Tao R, Emslie GJ, Mayes TL, et al. Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder. J Child Adolesc Psychopharmacol. 2010;20:423-430.
11. Masi G, Liboni F, Brovedani P. Pharmacotherapy of major depressive disorder in adolescents. Expert Opin Pharmacother. 2010;11:375-386.
12. Weisz JR, McCarty CA, Valeri SM. Effects of psychotherapy for depression in children and adolescents: a meta-analysis. Psychol Bull. 2006;132:132-149.
13. Klein JB, Jacobs RH, Reinecke MA. Cognitive-behavioral therapy for adolescent depression: a meta-analytic investigation of changes in effect-size estimates. J Am Acad Child Adolesc Psychiatry. 2007;46:1403-1413.
14. Zhou X, Hetrick SE, Cuijpers P, et al. Comparative efficacy and acceptability of psychotherapies for depression in children and adolescents: a systematic review and network metaanalysis. World Psychiatry. 2015;14:207-222.
15. Arnberg A, Ost LG. CBT for children with depressive symptoms: a meta-analysis. Cogn Behav Ther. 2014;43:275-288.
16. Forti-Buratti MA, Saikia R, Wilkinson EL, et al. Psychological treatments for depression in pre-adolescent children (12 years and younger): systematic review and meta-analysis of randomised controlled trials. Eur Child Adolesc Psychiatry. 2016 Mar. 11. [Epub ahead of print]
17. Ye X, Bapuji SB, Winters SE, et al. Effectiveness of Internetbased interventions for children, youth, and young adults with anxiety and/or depression: a systematic review and metaanalysis. BMC Health Serv Res. 2014;14:313.
18. Ebert DD, Zarski AC, Christensen H, et al. Internet and computer-based cognitive behavioral therapy for anxiety and depression in youth: a meta-analysis of randomized controlled outcome trials. PLoS One. 2015;10:e0119895.
19. Pennant ME, Loucas CE, Whittington C, et al. Computerised therapies for anxiety and depression in children and young people: a systematic review and meta-analysis. Behav Res Ther. 2015;67:1-18.
20. Cox GR, Callahan P, Churchill R, et al. Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents. Cochrane Database Syst Rev. 2014;11:CD008324.
21. Dubicka B, Elvins R, Roberts C, et al. Combined treatment with cognitive-behavioural therapy in adolescent depression: meta-analysis. Br J Psychiatry. 2010;197:433-440.
22. Cox GR, Fisher CA, De Silva S, et al. Interventions for preventing relapse and recurrence of a depressive disorder in children and adolescents. Cochrane Database Syst Rev. 2012;11:CD007504.
23. Vitiello B, Brent DA, Greenhill LL, et al. Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) study. J Am Acad Child Adolesc Psychiatry. 2009;48:997-1004.
24. Hetrick SE, McKenzie JE, Cox GR, et al. Newer generation antidepressants for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2012;11:CD004851.
25. Cipriani A, Zhou X, Del Giovane C, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet. 2016 June 8. [Epub ahead of print]
26. Wagner KD, Jonas J, Findling RL, et al. A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression. J Am Acad Child Adolesc Psychiatry. 2006;45:280-288.
27. Leonard HL, March J, Rickler KC, et al. Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997;36:725-736.
28. Hazell P, Mirzaie M. Tricyclic drugs for depression in children and adolescents. Cochrane Database Syst Rev. 2013;6:CD002317.
29. Adegbite-Adeniyi C, Gron B, Rowles BM, et al. An update on antidepressant use and suicidality in pediatric depression. Expert Opin Pharmacother. 2012;13:2119-2130.
30. Brent DA, Emslie GJ, Clarke GN, et al. Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry. 2009;166:418-426.
31. Lam RW, Kennedy SH. CPA Position Statement. Prescribing antidepressants for depression in 2005: Recent concerns and recommendations. Can J Psychiatry. 2004;49:I1-I6.
32. Lynch FL, Dickerson JF, Clarke G, et al. Incremental costeffectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings. Arch Gen Psychiatry. 2011;68:253-262.
33. Donaldson AE, Gordon MS, Melvin GA, et al. Addressing the needs of adolescents with treatment resistant depressive disorders: a systematic review of rTMS. Brain Stimul. 2014;7:7-12.
34. Ghaziuddin N, Kutcher SP, Knapp P, et al. Practice parameter for use of electroconvulsive therapy with adolescents. J Am Acad Child Adolesc Psychiatry. 2004;43:1521-1539.
35. Zhand N, Courtney DB, Flament MF. Use of electroconvulsive therapy in adolescents with treatment-resistant depressive disorders: a case series. J ECT. 2015;31:238-245.
36. Hirschtritt ME, Pagano ME, Christian KM, et al. Moderators of fluoxetine treatment response for children and adolescents with comorbid depression and substance use disorders. J Subst Abuse Treat. 2012;42:366-372.
37. Jacobs RH, Becker-Weidman EG, Reinecke MA, et al. Treating depression and oppositional behavior in adolescents. J Clin Child Adolesc Psychol. 2010;39:559-567.
38. Hilton RC, Rengasamy M, Mansoor B, et al. Impact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression. J Am Acad Child Adolesc Psychiatry. 2013;52:482-492.
39. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297:1683-1696.
40. Henry A, Kisicki MD, Varley C. Efficacy and safety of antidepressant drug treatment in children and adolescents. Mol Psychiatry. 2012;17:1186-1193.
41. Barbui C, Esposito E, Cipriani A. Selective serotonin reuptake inhibitors and risk of suicide: a systematic review of observational studies. CMAJ. 2009;180:291-297.
42. Gaynes BN, Gavin N, Meltzer-Brody S, et al. Perinatal depression: prevalence, screening accuracy, and screening outcomes. Evid Rep Technol Assess (Summ). 2005;119:1-8.
43. Gavin NI, Gaynes BN, Lohr KN, et al. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol. 2005;106(5, Pt 1):1071-1083.
44. Finer LB, Zolna MR. Unintended pregnancy in the United States: incidence and disparities, 2006. Contraception. 2011;84:478-485.
45. Le Strat Y, Dubertret C, Le Foll B. Child marriage in the United States and its association with mental health in women. Pediatrics. 2011;128:524-530.
46. Zuckerman B, Amaro H, Bauchner H, et al. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol. 1989;160(5, Pt 1):1107-1111.
47. Grote NK, Bridge JA, Gavin AR, et al. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry. 2010;67:1012-1024.
48. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63:898-906.
49. Bonari L, Pinto N, Ahn E, et al. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry. 2004;49:726-735.
50. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74:e321-e341.
51. Field T, Diego M, Hernandez-Reif M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev. 2006;29:445-455.
52. Deave T, Heron J, Evans J, et al. The impact of maternal depression in pregnancy on early child development. BJOG. 2008;115:1043-1051.
53. Bennett HA, Einarson A, Taddio A, et al. Depression during pregnancy: overview of clinical factors. Clin Drug Investig. 2004;24:157-179.
54. Sockol LE. A systematic review of the efficacy of cognitive behavioral therapy for treating and preventing perinatal depression. J Affect Disord. 2015;177:7-21.
55. Sockol LE, Epperson CN, Barber JP. A meta-analysis of treatments for perinatal depression. Clin Psychol Rev. 2011;31:839-849.
56. Dennis CL, Dowswell T. Interventions (other than pharmacological, psychosocial or psychological) for treating antenatal depression. Cochrane Database Syst Rev. 2013;7:CD006795.
57. Kim DR, Snell JL, Ewing GC, et al. Neuromodulation and antenatal depression: a review. Neuropsychiatr Dis Treat. 2015;11:975-982.
58. Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. pharmacological treatments. Can J Psychiatry. 2016;61(9):540-560.
59. Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. 2010;88:159-170.
60. Yonkers KA, Blackwell KA, Glover J, et al. Antidepressant use in pregnant and postpartum women. Annu Rev Clin Psychol. 2014;10:369-392.
61. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Antidepressant exposure during pregnancy and congenital malformations: is there an association? A systematic review and meta-analysis of the best evidence. J Clin Psychiatry. 2013;74:e293-e308.
62. Ross LE, Grigoriadis S, Mamisashvili L, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry. 2013;70:436-443.
63. Einarson A, Choi J, Einarson TR, et al. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry. 2009;54:242-246.
64. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74:e309-e320.
65. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and metaanalysis. BMJ. 2014;348:f6932.
66. Nulman I, Koren G, Rovet J, et al. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry. 2012;169:1165-1174.
67. Boukhris T, Sheehy O, Mottron L, et al. Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr. 2016;170:117-124.
68. Moehler E, Brunner R, Wiebel A, et al. Maternal depressive symptoms in the postnatal period are associated with longterm impairment of mother-child bonding. Arch Womens Ment Health. 2006;9:273-278.
69. O'Hara MW, McCabe JE. Postpartum depression: current status and future directions. Annu Rev Clin Psychol. 2013;9:379-407.
70. Molyneaux E, Howard LM, McGeown HR, et al. Antidepressant treatment for postnatal depression. Cochrane Database Syst Rev. 2014;9:CD002018.
71. Daley A, Jolly K, MacArthur C. The effectiveness of exercise in the management of post-natal depression: systematic review and meta-analysis. Fam Pract. 2009;26:154-162.
72. Daley AJ, Blamey RV, Jolly K, et al. A pragmatic randomized controlled trial to evaluate the effectiveness of a facilitated exercise intervention as a treatment for postnatal depression: the PAM-PeRS trial. Psychol Med. 2015;45:2413-2425.
73. Brandon AR, Crowley SK, Gordon JL, et al. Nonpharmacologic treatments for depression related to reproductive events. Curr Psychiatry Rep. 2014;16:526.
74. O'Mahen HA, Richards DA, Woodford J, et al. Netmums: a phase II randomized controlled trial of a guided Internet behavioural activation treatment for postpartum depression. Psychol Med. 2014;44:1675-1689.
75. O'Mahen HA, Woodford J, McGinley J, et al. Internet-based behavioral activation-treatment for postnatal depression (Netmums): a randomized controlled trial. J Affect Disord. 2013;150:814-822.
76. Pugh NE, Hadjistavropoulos HD, Dirkse D. A randomised controlled trial of therapist-assisted, Internet-delivered cognitive behavior therapy for women with maternal depression. PLoS One. 2016;11:e0149186.
77. Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: a systematic review. Hum Psychopharmacol. 2015;30:4-20.
78. Wisner KL, Hanusa BH, Perel JM, et al. Postpartum depression: a randomized trial of sertraline versus nortriptyline. J Clin Psychopharmacol. 2006;26:353-360.
79. Garcia KS, Flynn P, Pierce KJ, et al. Repetitive transcranial magnetic stimulation treats postpartum depression. Brain Stimul. 2010;3:36-41.
80. Moretti ME. Psychotropic drugs in lactation-Motherisk Update 2008. Can J Clin Pharmacol. 2009;16:e49-e57.
81. Crowley SK, Youngstedt SD. Efficacy of light therapy for perinatal depression: a review. J Physiol Anthropol. 2012;31:15.
82. Gressier F, Rotenberg S, Ait Tayeb AE, et al. Tobacco consumption concerns with the use of CYP1A2 metabolized antidepressants. Am J Psychiatry. 2015;172:909-910.
83. Gressier F, Rotenberg S, Cazas O, et al. Postpartum electroconvulsive therapy: a systematic review and case report. Gen Hosp Psychiatry. 2015;37:310-314.
84. Kim DR, Epperson CN, Weiss AR, et al. Pharmacotherapy of postpartum depression: an update. Expert Opin Pharmacother. 2014;15:1223-1234.
85. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric. 2012;15:105-114.
86. Bromberger JT, Matthews KA, Schott LL, et al. Depressive symptoms during the menopausal transition: the Study of Women's Health Across the Nation (SWAN). J Affect Disord. 2007;103(1-3):267-272.
87. Cohen LS, Soares CN, Vitonis AF, et al. Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles. Arch Gen Psychiatry. 2006;63:385-390.
88. Freeman EW, Sammel MD, Lin H, et al. Associations of hormones and menopausal status with depressed mood in women with no history of depression. Arch Gen Psychiatry. 2006;63:375-382.
89. Woods NF, Smith-DiJulio K, Percival DB, et al. Depressed mood during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study. Menopause. 2008;15(2):223-232.
90. Frey BN, Lord C, Soares CN. Depression during menopausal transition: a review of treatment strategies and pathophysiological correlates. Menopause Int. 2008;14:123-128.
91. Clayton AH, Kornstein SG, Dunlop BW, et al. Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebocontrolled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2013;74:1010-1017.
92. Kornstein SG, Jiang Q, Reddy S, et al. Short-term efficacy and safety of desvenlafaxine in a randomized, placebocontrolled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry. 2010;71:1088-1096.
93. Kornstein SG, Clayton AH, Bao W, et al. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women. J Womens Health (Larchmt). 2015;24:281-290.
94. Dias RS, Kerr-Corrêa F, Moreno RA. Efficacy of hormone therapy with and without methyltestosterone augmentation of venlafaxine in the treatment of postmenopausal depression: a double-blind controlled pilot study. Menopause. 2006;13:202-211.
95. Soares CN, Almeida OP, Joffe H, et al. Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry. 2001;58:529-534.
96. Schmidt PJ, Nieman L, Danaceau MA, et al. Estrogen replacement in perimenopause-related depression: a preliminary report. Am J Obstet Gynecol. 2000;183:414-420.
97. Morrison MF, Kallan MJ, Ten Have T, et al. Lack of efficacy of estradiol for depression in postmenopausal women: a randomized, controlled trial. Biol Psychiatry. 2004;55:406-412.
98. Khoshbooii R, Hassan SA, Hamzah MSG, et al. Effectiveness of group cognitive behavioral therapy on depression among Iranian women around menopause. Aust J Basic Appl Sci. 2011;5:991-995.
99. Brandon AR, Minhajuddin A, Thase ME, et al. Impact of reproductive status and age on response of depressed women to cognitive therapy. J Womens Health (Larchmt). 2013;22:58-66.
100. Dørmænen A, Heimdal MR, Wang CE, et al. Depression in postmenopause: a study on a subsample of the Acupuncture on Hot Flushes Among Menopausal Women (ACUFLASH) study. Menopause. 2011;18:525-530.
101. Ismail Z, Fischer C, McCall WV. What characterizes late-life depression? Psychiatr Clin North Am. 2013;36:483-496.
102. Alexopoulos GS, Meyers BS, Young RC, et al. 'Vascular depression' hypothesis. Arch Gen Psychiatry. 1997;54:915-922.
103. Krishnan KR, Taylor WD, McQuoid DR, et al. Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. Biol Psychiatry. 2004;55:390-397.
104. Ismail Z, Malick A, Smith EE, et al. Depression versus dementia: is this construct still relevant? Neurodegener Dis Manag. 2014;4:119-126.
105. Ismail Z, Smith EE, Geda Y, et al. Neuropsychiatric symptoms as early manifestations of emergent dementia: provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12:195-202.
106. Cuijpers P, van Straten A, Smit F. Psychological treatment of late-life depression: a meta-analysis of randomized controlled trials. Int J Geriatr Psychiatry. 2006;21:1139-1149.
107. Pinquart M, Duberstein PR, Lyness JM. Treatments for laterlife depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry. 2006;163:1493-1501.
108. Huang AX, Delucchi K, Dunn LB, et al. A systematic review and meta-analysis of psychotherapy for late-life depression. Am J Geriatr Psychiatry. 2015;23:261-273.
109. Kirkham JG, Choi N, Seitz DP. Meta-analysis of problem solving therapy for the treatment of major depressive disorder in older adults. Int J Geriatr Psychiatry. 2016;31:526-535.
110. Ismail Z, Pollock BG. General principles of pharmacologic therapy. In: Tasman A, Kay J, Lieberman JA, First MB, Maj M, editors. Psychiatry. 3rd ed. Chichester (UK): John Wiley; 2008. pp. 2097-2111.
111. Topiwala A, Chouliaras L, Ebmeier KP. Prescribing selective serotonin reuptake inhibitors in older age. Maturitas. 2014;77:118-123.
112. De Picker L, Van Den Eede F, Dumont G, et al. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. Psychosomatics. 2014;55:536-547.
113. Coupland C, Dhiman P, Morriss R, et al. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343:d4551.
114. Cooke MJ, Waring WS. Citalopram and cardiac toxicity. Eur J Clin Pharmacol. 2013;69:755-760.
115. Schiff GD, Galanter WL, Duhig J, et al. Principles of conservative prescribing. Arch Intern Med. 2011;171:1433-1440.
116. Nelson JC, Delucchi K, Schneider LS. Efficacy of second generation antidepressants in late-life depression: a metaanalysis of the evidence. Am J Geriatr Psychiatry. 2008;16:558-567.
117. Alexopoulos GS, Katz IR, Reynolds CF III, et al. The expert consensus guideline series: pharmacotherapy of depressive disorders in older patients. Postgrad Med. 2001 Oct; Spec No Pharmacotherapy: 1-86.
118. Canadian Coalition for Seniors' Mental Health. National guidelines for seniors' mental health-the assessment and treatment of depression [Internet]. 2006. Available from: http://www.ccsmh.ca/en/guidelinesUsers.cfm
119. Mulsant BH, Blumberger DM, Ismail Z, et al. A systematic approach to pharmacotherapy for geriatric major depression. Clin Geriatr Med. 2014;30:517-534.
120. Roose SP, Sackeim HA, Krishnan KR, et al. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry. 2004;161:2050-2059.
121. Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry. 2008;16:14-20.
122. Kasper S, de Swart H, Friis Andersen H. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry. 2005;13:884-891.
123. Seitz DP, Gill SS, Conn DK. Citalopram versus other antidepressants for late-life depression: a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2010;25:1296-1305.
124. Tollefson GD, Bosomworth JC, Heiligenstein JH, et al. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group. Int Psychogeriatr. 1995;7:89-104.
125. Rapaport MH, Schneider LS, Dunner DL, et al. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry. 2003;64:1065-1074.
126. Mukai Y, Tampi RR. Treatment of depression in the elderly: a review of the recent literature on the efficacy of single-versus dual-action antidepressants. Clin Ther. 2009;31:945-961.
127. Kok RM, Nolen WA, Heeren TJ. Efficacy of treatment in older depressed patients: a systematic review and metaanalysis of double-blind randomized controlled trials with antidepressants. J Affect Disord. 2012;141:103-115.
128. Tedeschini E, Levkovitz Y, Iovieno N, et al. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry. 2011;72:1660-1668.
129. Thorlund K, Druyts E, Wu P, et al. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotoninnorepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc. 2015;63:1002-1009.
130. Nelson JC, Delucchi KL, Schneider LS. Moderators of outcome in late-life depression: a patient-level meta-analysis. Am J Psychiatry. 2013;170:651-659.
131. Pimontel MA, Rindskopf D, Rutherford BR, et al. A metaanalysis of executive dysfunction and antidepressant treatment response in late-life depression. Am J Geriatr Psychiatry. 2016;24:31-41.
132. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27:215-223.
133. Heun R, Ahokas A, Boyer P, et al. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry. 2013;74:587-594.
134. Kok RM, Heeren TJ, Nolen WA. Continuing treatment of depression in the elderly: a systematic review and metaanalysis of double-blinded randomized controlled trials with antidepressants. Am J Geriatr Psychiatry. 2011;19:249-255.
135. Steffens DC, Nelson JC, Eudicone JM, et al. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. Int J Geriatr Psychiatry. 2011;26:564-572.
136. Lenze EJ, Mulsant BH, Blumberger DM, et al. Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:2404-2412.
137. Katila H, Mezhebovsky I, Mulroy A, et al. Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry. 2013;21:769-784.
138. Montgomery SA, Altamura AC, Katila H, et al. Efficacy of extended release quetiapine fumarate monotherapy in elderly patients with major depressive disorder: secondary analyses in subgroups of patients according to baseline anxiety, sleep disturbance, and pain levels. Int Clin Psychopharmacol. 2014;29:93-105.
139. Gareri P, Segura-Garcia C, Manfredi VG, et al. Use of atypical antipsychotics in the elderly: a clinical review. Clin Interv Aging. 2014;9:1363-1373.
140. Unützer J, Katon W, Callahan CM, et al. Collaborative care management of late-life depression in the primary care setting: a randomized controlled trial. JAMA. 2002;288:2836-2845.
141. Unützer J, Katon W, Williams JW Jr, et al. Improving primary care for depression in late life: the design of a multicenter randomized trial. Med Care. 2001;39:785-799.
142. Mulsant BH, Alexopoulos GS, Reynolds CF III, et al. Pharmacological treatment of depression in older primary care patients: the PROSPECT algorithm. Int J Geriatr Psychiatry. 2001;16:585-592.
143. Alexopoulos GS, Katz IR, Bruce ML, et al. Remission in depressed geriatric primary care patients: a report from the PROSPECT study. Am J Psychiatry. 2005;162:718-724.
144. Cooper C, Katona C, Lyketsos K, et al. A systematic review of treatments for refractory depression in older people. Am J Psychiatry. 2013;168:681-688.
145. Kok RM, Nolen WA, Heeren TJ. Outcome of late-life depression after 3 years of sequential treatment. Acta Psychiatr Scand. 2009;119:274-281.